Pr. Hoesli is the head of the Stem Cell Bioprocessing Laboratory at McGill University. She is associate director of the Quebec Cell, Tissue and Gene Therapy Network – ThéCell, and a member of the McGill Regenerative Medicine network executive committee. She is a biochemical engineer with expertise in bioprocess development, stem cell culture optimization and encapsulation device engineering. Her research aims to develop bioprocesses to produce and transplant therapeutic cells to treat diabetes and cardiovascular disease. Her laboratory studies how cell culture materials impact stem cell and progenitor cell differentiation into useful therapeutic products. To biomanufacture cell-based products at scale, she works with companies and governmental organizations to tailor bioreactor design and operation parameters. To improve cell survival after transplantation, her laboratory is developing vascular biomaterials and 3D printing methods to create vascularized tissues. Over the past 5 years, Prof. Hoesli and her team have published over 2 articles in leading bioprocess engineering journals, as well as several patents related to cell culture materials and transplantation devices. Her leadership in bioengineering was recognized through the 2014 Martin Sinacore Outstanding Young Investigator Award from Engineering Conferences International & Biogen Idec, as well as the 2019 “Étoiles effervescence” award from Montreal InVivo. Prof. Hoesli is co-founder and CSO of two McGill spinoff companies based on technologies developed by her laboratory.
STEM CELL BIOPROCESSING LABORATORY
Canada Research Chair in Cellular Therapy Bioprocess Engineering
